Geode Capital Management LLC Boosts Stock Position in Vaxart, Inc. (NASDAQ:VXRT)

Geode Capital Management LLC grew its stake in shares of Vaxart, Inc. (NASDAQ:VXRT) by 15.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,543,228 shares of the biotechnology company’s stock after buying an additional 346,725 shares during the period. Geode Capital Management LLC’s holdings in Vaxart were worth $2,160,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Millennium Management LLC lifted its position in shares of Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after acquiring an additional 2,095,274 shares in the last quarter. Monaco Asset Management SAM purchased a new stake in shares of Vaxart in the second quarter worth $402,000. XTX Topco Ltd raised its position in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after buying an additional 122,387 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. raised its position in shares of Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after buying an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Vaxart Stock Performance

Shares of VXRT stock opened at $0.88 on Wednesday. Vaxart, Inc. has a 52-week low of $0.52 and a 52-week high of $1.54. The company has a market capitalization of $199.36 million, a PE ratio of -2.14 and a beta of 0.62. The business’s fifty day moving average is $0.66 and its 200 day moving average is $0.73.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.